Home › NDC Lookup › Ingredients › Calcipotriene › 66993-0877-78
Calcipotriene 50 ug/g Cream — NDC 66993-0877-78 package photo

Calcipotriene 50 ug/g Cream

by Prasco Laboratories · 1 TUBE in 1 CARTON (66993-877-78) / 120 g in 1 TUBE
NDC 66993-0877-78
🏷️ FDA NDC (as labeled) 66993-877-78 billing pads the product segment with a zero
This package
Contains120 g in 1 tube Cost per g$1.04 NADAC Per package$124.84 / 120 g Pack sizes2 compare ↓
Also priced by: Medicaid pays $1.19/unit · Part D plans $1.86/unit — full pricing hub ↓
Also comes in: 60 g 66993-0877-61
Rx only Brand On market Non-controlled
🗂️ Data synced Jul 24, 2026 · sources: openFDA · FDA label (DailyMed) · FDA Orange & Purple Book · First Databank · CMS NADAC, ASP, Medicare & Medicaid · RxNorm
📋 All sources & update times →

This page is curated, coded, and maintained by

Compiled from public FDA, CMS, DailyMed, NADAC, and related drug data sources. Editorial policy

🆔 Identity & classification

FDA NDC (as labeled) 66993-877-78
Product NDC 66993-877
11-digit billing NDC 66993087778
NCPDP billing unit GM — per gram (weight)
RxCUI 313921
UNII 143NQ3779B
Application # NDA020554
SPL Set ID 377eafda-737c-4ba2-9ec5-61209b8814ed
Established class (EPC) Vitamin D Analog
Chemical class Vitamin D
DEA schedule Non-controlled
Marketing category NDA AUTHORIZED GENERIC
Marketing status On market
FDA listing status Listed (active directory)
Marketing start 1996-10-01
Route TOPICAL
Dosage form CREAM
Substance CALCIPOTRIENE
GPI-14 90250025003710
GPI class Calcipotriene
GCN Seq No 021134
GCN 01851
HICL code 013331
Ingredient (HICL) Calcipotriene
HIC1 code L
Therapeutic class — broad (HIC1) Skin/Subcutaneous Tissue
HIC2 code L5
Therapeutic class — intermediate (HIC2) Keratolytics/Keratoplastics
HIC3 code L5F
Therapeutic class — specific (HIC3) Antipsoriatics Agents
AHFS code 84:24.12.00
AHFS class Basic Ointments And Protectants
FDB label name CALCIPOTRIENE 0.005% CREAM
FDB brand name Calcipotriene
Legend status F — Federal legend — prescription drug or device
TE code (Orange Book) AB · RLD · RS
Why two NDCs? The FDA registers this code as 66993-877-78 — a 5-3-2 layout, and that's what's printed on the package and shown on DailyMed. For insurance claims, every NDC is standardized to a uniform 11-digit 5-4-2 format by adding a zero to the product segment → 66993-0877-78. Same drug, same package — only the format differs.
Where does this data come from?
Identifiers from the FDA openFDA NDC Directory and Structured Product Labeling; RxCUI from RxNorm (NLM); GPI from Medi-Span; GCN / HIC / AHFS / legend from First Databank.

🏷️ RxNorm drug class

This medicine belongs to the Vitamin D Analog class.

Pharmacologic class Vitamin D Analog
Drug family (ATC) Other antipsoriatics for topical use
Where does this data come from?
Therapeutic classes from RxNorm RxClass (U.S. National Library of Medicine) — Established Pharmacologic Class (FDA), ATC drug family (WHO) and mechanism of action, matched by this product’s RxCUI.

🏭 Manufacturer & labeler

LabelerPrasco Laboratories
Application holderLEO PHARMA AS
FDA applicationNDA020554 (NDA AUTHORIZED GENERIC)
Labeler code66993
First marketedOct 1996
Product typeHuman Prescription Drug
Portfolio106 products on file
The labeler markets the product; the application holder owns the FDA approval. They’re often the same company but can differ (e.g. a repackager or an authorized generic). A mailing address / phone appears here when the manufacturer includes it in the product’s FDA label (not all do).
Where does this data come from?
Labeler, application holder and registered establishment from the FDA openFDA NDC Directory and Drugs@FDA; address/contact from the product’s FDA label.

🩺 Clinical

Label name CALCIPOTRIENE 0.005% CREAM Ingredient Calcipotriene
📖 What it is MedlinePlus · NLM

Calcipotriene is used to treat psoriasis (a skin disease in which red, scaly patches form due to increased production of skin cells on some areas of the body). Calcipotriene is in a class of medications called synthetic vitamin D3 derivatives. It works by slowing the excessive production of skin cells.

Read the full MedlinePlus article ↗
📗 Our plain-language guide HelloPharmacist
  • Calcipotriene is not a steroid at all — it's a synthetic form of vitamin D3. While steroid creams work by suppressing inflammation, calcipotriene is thought to work by binding to v...
  • What exactly is calcipotriene, and how is it different from a steroid cream?
  • No — calcipotriene should not be applied to the face. The label is clear on this for all product forms. If you have psoriasis on your face, talk to your dermatologist about other o...
  • Can I use this on my face if my psoriasis is there too?
📖 Read our full Calcipotriene Topical guide →
Where does this data come from?
Plain-language summary from MedlinePlus (U.S. National Library of Medicine); supplement & herbal interactions and nutrient depletion data from the Natural Medicines database; our full guide is HelloPharmacist editorial content.

🧪 Inactive Ingredients / Excipients

Inactive ingredients, also called excipients, are components of the drug product other than the active ingredient. They may include fillers, dyes, coatings, preservatives, flavors, or other formulation ingredients.

💡 Tap an ingredient (hover on desktop) to see what it is and why it’s used.

  • UNII 7QWA1RIO01
    A synthetic form of vitamin E used as an antioxidant in medicines. It prevents oils and fats in the formulation from breaking down, helping the drug remain stable and effective during storage.
  • UNII I835H2IHHX
    A waxy substance derived from plant oils, used as an emulsifier and solubilizer to help mix oil and water ingredients together and keep them blended throughout the product's shelf life.
  • UNII 2DMT128M1S
    A waxy solid derived from plant or animal sources. It acts as an emulsifier to blend oil and water components, and also thickens the medicine to give it the right texture and consistency.
  • UNII H5RIZ3MPW4
    A chemical preservative used to prevent bacterial and fungal growth in medicines. It helps extend shelf life and maintain product safety during storage and use.
  • UNII 1NKX3648J9
    A synthetic antimicrobial compound used as a preservative in medicines and topical products to prevent bacterial and fungal growth, helping keep the medication safe and effective during storage.
  • UNII 7FLD91C86K
    Edetate disodium is a chemical compound that binds and removes certain metal ions. In medicines, it acts as a preservative and stabilizer by preventing metals like calcium from interfering with the product's shelf life and consistency.
  • UNII PDC6A3C0OX
    Glycerin is a clear, thick liquid derived from plant oils or fats. It acts as a humectant to retain moisture, a sweetener, and a solvent in medications.
  • UNII T5L8T28FGP
    Mineral oil is a clear, odorless liquid derived from crude oil. It acts as a lubricant and emollient in medications, helping pills slide smoothly during manufacturing and aiding moisture retention in topical products.
  • UNII 4T6H12BN9U
    Petrolatum is a purified mineral oil-based jelly derived from petroleum. In medicines, it acts as an emollient, lubricant, and moisture barrier to soften skin, reduce friction, and help prevent water loss from formulations.
  • UNII GR686LBA74
    Sodium phosphate, dibasic is a salt derived from phosphoric acid. It acts as a buffer to help maintain the medicine's pH balance and may serve as a binder or filler in tablets and capsules.
  • UNII 059QF0KO0R
    Water is a liquid solvent that dissolves and mixes ingredients together in liquid medicines, syrups, and injections. It helps distribute the active drug evenly throughout the product.

11 inactive ingredients listed in the exact product block matched to this NDC.

Where does this data come from?
Data sourced from official FDA Structured Product Labeling (SPL) via DailyMed — ingredient classCode="IACT" elements from the exact product block matched by this NDC. Label-section narrative from DailyMed / the openFDA label index is shown separately when available.

Inactive ingredient FAQ

Are inactive ingredients the same for every manufacturer?
No. Inactive ingredients can differ by manufacturer, dosage form, strength, and package / product version.
Why might an inactive ingredient be missing?
Some SPLs do not provide a complete structured inactive-ingredient list, and older or unusual labels may only include the information in narrative text.
Can inactive ingredients matter?
Yes. They can matter for allergies, intolerances, dyes, gluten / lactose concerns, preservatives, and formulation differences — but confirm with a pharmacist or the manufacturer when it’s clinically important.

💲 Pricing

A drug doesn't have one price. Each row is a different public payment system, and none is what you'd pay at the counter — that depends on your insurance. The ⓘ on each row explains what it measures.

Price systemPer gPer package
Retail pharmacies payNADAC · weekly $1.040 $124.84 / 120 g
Medicaid paysCMS SDUD · 12 mo $1.19 $142.49 / 120 g
Medicare drug plans payPart D · Q2 2026 $1.86 $223.50 / 120 g
NADAC price history (per g) — tap or hover for the price & month
Dec 2021 Jul 2022 Jan 2026 Aug 2026 $1.487 $0.832
▼ Down 12% over the last 22 months.
Where does this data come from?
NADAC (National Average Drug Acquisition Cost) is the CMS weekly pharmacy-acquisition-cost survey — what pharmacies pay. ASP (Average Sales Price) is the CMS Medicare Part B drug-payment file, published quarterly. Medicaid pays is computed by us from CMS State Drug Utilization Data (total reimbursed ÷ units, trailing 12 months) — gross of rebates and inclusive of dispensing fees, so it reflects what Medicaid paid, not an acquisition cost. Medicare drug plans pay is the median negotiated point-of-sale unit cost across plans listing this NDC in the CMS quarterly Prescription Drug Plan pricing files, before rebates. The VA pays is the federal contract price (FSS, and the statutory Big 4 ceiling where listed) from the VA National Acquisition Center pharmaceutical price file. All are free public government data; each measures a different payer, so the figures are not directly comparable.

🔁 Therapeutic equivalents

ProductLabelerPackNADAC/unitTEStatusPrice vs. this
Calcipotriene 50 ug/gthis 66993-0877-78 Prasco 1 tube $1.040 AB Availability likely —
calcipotriene 50 ug/g 16714-0763-01 Northstar 1 tube $1.087 AB Availability likely +5%
calcipotriene 50 ug/g 68462-0501-65 Glenmark 1 tube $1.087 AB Availability likely +5%
calcipotriene 50 ug/g 66993-0878-61 Prasco 1 tube $2.123 AB Availability likely +104%
Calcipotriene 50 ug/g 68462-0310-65 Glenmark 60 g $2.123 AB Availability likely +104%
Trionex 72835-0902-02 V2 1 kit — — FDA listed —
About this product: this is an authorized generic — the brand-name product marketed without its brand name. Other versions are listed above, least expensive first.
Where does this data come from?
Equivalents are other NDCs of the same ingredient, form and route from the openFDA NDC Directory, ranked least-expensive-first by NADAC. Therapeutic-equivalence (AB) ratings come from the FDA Orange Book; biologics use the FDA Purple Book for biosimilar & interchangeable status.

⏳ Availability & generic status

🏛️
1996
On the market since
Oct 1996
📍
2026
Currently FDA-listed
30 years listed
🔓
·
Generic versions listed
see equivalents
✅Generic appears available

FDA-approved generic versions are listed, and recent pricing/market data suggests they may be available — see Therapeutic equivalents.

Where does this data come from?
Patents and exclusivity from the FDA Orange Book (small-molecule drugs), refreshed from public FDA data. Generic launch timing is an estimate, not a guarantee.

🗺️ Medicaid utilization & spend

📍 This exact package only: Medicaid data is reported per full 11-digit NDC — labeler, product and pack size — so every number here is for 66993-0877-78, not the drug overall. Other pack sizes report separately.
💊 Pharmacy benefit only: These are Medicaid outpatient pharmacy claims, billed by NDC. They exclude the medical benefit — clinic- or hospital-administered drugs billed under HCPCS J-codes — so drugs used mostly that way (e.g. Avastin, Lucentis, Keytruda) can look low or missing here. That’s expected, not an error.
📅 Q1 2025 – Q4 2025 · 4 quarters of data
ⓘ The newest quarter is usually incomplete when first published; states restate recent quarters in later CMS releases, so the latest figures typically revise upward. State coverage-policy changes can also shift quarter-to-quarter totals.
Prescriptions last 4 qtrs
2.8K
Units reimbursed last 4 qtrs
341K
Gross reimbursed last 4 qtrs
$404.9K
Avg / prescription
$144.66
Avg / unit
$1.1874
Latest quarter Q4 2025
603Rx
Medicaid pays / g
$1.1874
gross reimbursed
vs
NADAC / g
$1.0403
acquisition cost
=
Spread
+$0.1471
+14% vs cost
What Medicaid paid per g (before rebates; includes the pharmacy’s dispensing fee) compared with NADAC — the average price pharmacies pay to buy the drug. A positive spread means Medicaid reimbursed more than the purchase price, before manufacturer rebates.
Fee-for-service vs managed care ⓘ
58% FFS 42% MCO
Fee-for-service · 1,618 Rx Managed care · 1,181 Rx
State Medicaid map
Alaska: no data reported AK Maine: no data reported ME Washington: 5,040 units · 64.5 per 100k residents WA Idaho: no data reported ID Montana: no data reported MT North Dakota: no data reported ND Minnesota: no data reported MN Wisconsin: no data reported WI Michigan: no data reported MI New York: 61,478 units · 314 per 100k residents NY Vermont: no data reported VT New Hampshire: no data reported NH Oregon: 3,360 units · 79.4 per 100k residents OR Nevada: no data reported NV Wyoming: no data reported WY South Dakota: no data reported SD Iowa: 1,320 units · 41.2 per 100k residents IA Illinois: 14,460 units · 115 per 100k residents IL Indiana: 10,800 units · 157 per 100k residents IN Ohio: 23,340 units · 198 per 100k residents OH Pennsylvania: 25,440 units · 196 per 100k residents PA New Jersey: 5,160 units · 55.5 per 100k residents NJ Massachusetts: 4,560 units · 65.1 per 100k residents MA California: 128,073 units · 329 per 100k residents CA Utah: no data reported UT Colorado: 1,620 units · 27.6 per 100k residents CO Nebraska: no data reported NE Missouri: no data reported MO Kentucky: 8,040 units · 178 per 100k residents KY West Virginia: no data reported WV Virginia: 12,240 units · 140 per 100k residents VA Maryland: 4,680 units · 75.7 per 100k residents MD Connecticut: 3,240 units · 89.6 per 100k residents CT Rhode Island: no data reported RI Arizona: no data reported AZ New Mexico: no data reported NM Kansas: no data reported KS Arkansas: no data reported AR Tennessee: no data reported TN North Carolina: 13,350 units · 123 per 100k residents NC South Carolina: 1,320 units · 24.6 per 100k residents SC Delaware: no data reported DE Oklahoma: no data reported OK Louisiana: no data reported LA Mississippi: no data reported MS Alabama: no data reported AL Georgia: no data reported GA D.C.: no data reported DC Hawaii: no data reported HI Texas: no data reported TX Florida: 13,500 units · 59.7 per 100k residents FL
Units reimbursed · per 100k residents
24.6329
gray = no data reported ⓘ
Colors are per 100,000 residents, so big states don’t automatically dominate. Tap or hover a state for its actual totals.
Tap or hover a state
…for its Medicaid breakdown
🏆 Top states by units · per 100k residents
1 California 329 /100k
2 New York 314 /100k
3 Ohio 198 /100k
4 Pennsylvania 196 /100k
5 Kentucky 178 /100k
6 Indiana 157 /100k
7 Virginia 140 /100k
8 North Carolina 123 /100k
National units — by quarter
💵 About the dollar figures: “reimbursed” is what Medicaid paid pharmacies before confidential manufacturer rebates, so the program’s real net cost is lower than these numbers. Fee-for-service and managed-care claims are combined unless split above. Source: CMS State Drug Utilization Data; per-100k rates use 2023 Census population estimates.

💊 Medicaid utilization by pack size

Medicaid (SDUD) totals over the four most recent reported quarters for every package size of this drug — handy when a specific package (e.g. a starter/titration pack) carries little or no Medicaid volume on its own.
1 tube66993-0877-61 19,462 Rx · $1,782,074
1 tube this page66993-0877-78 2,799 Rx · $404,916
Drug total (last 4 qtrs): 22,261 Rx · 1,695,618 units · $2,186,990 gross reimbursed
Tap a pack size to open its page. Source: CMS State Drug Utilization Data, last 4 quarters.

📊 Medicare Part D spend CMS · PART D · 2026 (Q1)

Medicare Part D (outpatient prescription) spending for Calcipotriene — the program that covers self-administered drugs. 6 manufacturers.
⚠️ Drug-level data: CMS publishes Part D spending by drug, not by NDC — these figures combine every manufacturer, strength and package size sold under the name Calcipotriene. That’s a different level of aggregation than the Medicaid card above, which is specific to this exact 11-digit NDC (pack size included), so the two aren’t directly comparable.
Period
Total Part D spend
$6.34M
Claims incl. refills
37.8K
Beneficiaries
29.3K
Spend / beneficiary
$215.99
Spend / claim
$167.76
Trend by period
💵 About the dollar figures: spending is what Part D plans paid before confidential manufacturer rebates, so the program’s real net cost is lower. A blank patient count means fewer than 11 people — CMS hides counts that small to protect privacy. Source: CMS Medicare Quarterly Part D Spending by Drug (data.cms.gov), updated quarterly.

🔬 Reported adverse events (FAERS)

Read carefully: FAERS reports are voluntary and unverified. Counts are not incidence, do not establish causation, are subject to reporting bias, and cannot be used to compare one drug to another. Shown for signal context only. Reports for Calcipotriene — the ingredient across all brands.

Top reported reactions

Psoriasis1,364
Diarrhoea433
Headache363
Pruritus360
Nausea359
Arthralgia345
Rash333

Age at onset

Neonate1
Child11
Adolescent11
Adult1,076
Elderly410

Reporter sex

6,726 reports
Male · 45%
Female · 54%
Unknown · 0%

Serious outcomes

Hospitalization1,215
Death183
Disabling106
Reports over time (by year) — tap or hover for the count & year
2019 2021 2023 2026 1,257 197
Most recent year is provisional (FAERS lags ~3 months).
Where does this data come from?
Adverse-event reports from the FDA Adverse Event Reporting System (FAERS) via openFDA. FAERS reports are voluntary and unverified — counts are not incidence and don’t establish causation.

📦 Packaging — all sizes for this product

Package NDCDescription Per unit Per pack Marketing startStatus
66993-0877-61 1 TUBE in 1 CARTON (66993-877-61) / 60 g in 1 TUBE $1.09 / g $65.24 1996-10-01 Active
66993-0877-78 You're viewing this 1 TUBE in 1 CARTON (66993-877-78) / 120 g in 1 TUBE $1.04 / g $124.83 1996-10-01 Active

This pack has the lowest per-g cost of the 2 priced pack sizes ($1.04 NADAC).

This pack accounts for about 13% of this product's recent Medicaid fills; most go to a different pack size. See all packs ↓

Pack size FAQ

What quantity is in NDC 66993-0877-78?
NDC 66993-0877-78 is listed by the FDA — 1 tube in 1 carton / 120 g in 1 tube.
What NDC number is used to bill for this package of Calcipotriene 50 ug/g Cream?
Bill NDC 66993-0877-78 — the 11-digit billing format is 66993087778. Pharmacy and medical claims use the 11-digit form; the FDA label may print a shorter form of the same code.

Prices are the latest CMS NADAC pharmacy acquisition cost per NDC; per-pack figures are per-unit × pack quantity, shown only when the pack is denominated in the same measure NADAC prices.

📄 Full prescribing information FDA SPL

The complete FDA label for this product — the official prescribing information, verbatim, section by section. Jump with a chip, search within the label, or expand everything.
🎯 Indications and Usage ⏱️ Dosage and Administration ⛔ Contraindications ⚠️ Warnings 🤒 Adverse Reactions 🤰 Pregnancy 🧒 Pediatric Use 🧓 Geriatric Use 🆘 Overdosage 🧬 Clinical Pharmacology 📦 How Supplied / Storage and Handling 📦 Storage and Handling 📋 Description 💬 Information for Patients
🎯 Indications and Usage 30 words ▾

INDICATIONS AND USAGE Calcipotriene Cream, 0.005%, is indicated for the treatment of plaque psoriasis. The safety and effectiveness of topical calcipotriene in dermatoses other than psoriasis have not been established.

⏱️ Dosage and Administration 38 words ▾

DOSAGE AND ADMINISTRATION Apply a thin layer of Calcipotriene Cream to the affected skin twice daily and rub in gently and completely. The safety and efficacy of Calcipotriene Cream have been demonstrated in patients treated for eight weeks.

⛔ Contraindications 46 words ▾

CONTRAINDICATIONS Calcipotriene Cream is contraindicated in those patients with a history of hypersensitivity to any of the components of the preparation. It should not be used by patients with demonstrated hypercalcemia or evidence of vitamin D toxicity. Calcipotriene Cream should not be used on the face.

⚠️ Warnings 16 words ▾

WARNINGS Contact dermatitis, including allergic contact dermatitis, has been observed with the use of Calcipotriene Cream.

🤒 Adverse Reactions 2 words ▾

ADVERSE REACTIONS

🤰 Pregnancy 177 words ▾

Pregnancy Teratogenic Effects Studies of teratogenicity were done by the oral route where bioavailability is expected to be approximately 40-60% of the administered dose. Increased rabbit maternal and fetal toxicity was noted at 12 μg/kg/day (132 μg/m 2 /day). Rabbits administered 36 μg/kg/day (396 μg/m 2 /day) resulted in fetuses with a significant increase in the incidences of pubic bones, forelimb phalanges, and incomplete bone ossification.

In a rat study, oral doses of 54 μg/kg/day (318 μg/m 2 /day) resulted in a significantly higher incidence of skeletal abnormalities consisting primarily of enlarged fontanelles and extra ribs. The enlarged fontanelles are most likely due to calcipotriene's effect upon calcium metabolism. The maternal and fetal calculated no-effect exposures in the rat (43.2 μg/m 2 /day) and rabbit (17.6 μg/m 2 /day) studies are approximately equal to the expected human systemic exposure level (18.5 μg/m 2 /day) from dermal application.

There are no adequate and well-controlled studies in pregnant women. Therefore, Calcipotriene Cream should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus.

🧒 Pediatric Use 46 words ▾

Pediatric Use Safety and effectiveness of Calcipotriene Cream in pediatric patients have not been established. Because of a higher ratio of skin surface area to body mass, pediatric patients are at greater risk than adults of systemic adverse effects when they are treated with topical medication.

🧓 Geriatric Use 59 words ▾

Geriatric Use Of the total number of patients in clinical studies of calcipotriene cream, approximately 15% were 65 or older, while approximately 3% were 75 and over. There were no significant differences in adverse events for subjects over 65 years compared to those under 65 years of age. However, the greater sensitivity of older individuals cannot be ruled out.

🆘 Overdosage 44 words ▾

OVERDOSAGE Topically applied calcipotriene can be absorbed in sufficient amounts to produce systemic effects. Elevated serum calcium has been observed with excessive use of topical calcipotriene. If elevation in serum calcium should occur, discontinue treatment until normal calcium levels are restored. (See PRECAUTIONS .)

🧬 Clinical Pharmacology 165 words ▾

CLINICAL PHARMACOLOGY In humans, the natural supply of vitamin D depends mainly on exposure to the ultraviolet rays of the sun for conversion of 7-dehydrocholesterol to vitamin D 3 (cholecalciferol) in the skin. Calcipotriene is a synthetic analog of vitamin D 3 . Clinical studies with radiolabelled calcipotriene ointment indicate that approximately 6% (± 3%, SD) of the applied dose of calcipotriene is absorbed systemically when the ointment is applied topically to psoriasis plaques, or 5% (± 2.6%, SD) when applied to normal skin, and much of the absorbed active is converted to inactive metabolites within 24 hours of application.

Systemic absorption of the cream has not been studied. Vitamin D and its metabolites are transported in the blood, bound to specific plasma proteins. The active form of the vitamin, 1,25-dihydroxy vitamin D 3 (calcitriol), is known to be recycled via the liver and excreted in the bile.

Calcipotriene metabolism following systemic uptake is rapid, and occurs via a similar pathway to the natural hormone.

📦 How Supplied / Storage and Handling 20 words ▾

HOW SUPPLIED Calcipotriene Cream, 0.005% is available in: 60 gram aluminum tubes (NDC 66993-877-61) 120 gram aluminum tubes (NDC 66993-877-78)

📦 Storage and Handling 15 words ▾

STORAGE Store at controlled room temperature 15°C - 25°C (59°F - 77°F). Do not freeze.

📋 Description 96 words ▾

DESCRIPTION Calcipotriene Cream, 0.005% contains calcipotriene monohydrate, a synthetic vitamin D 3 derivative, for topical dermatological use. Chemically, calcipotriene monohydrate is (5Z,7E,22E,24S)-24-cyclopropyl-9,10-secochola-5,7,10(19),22-tetraene-1α,3β,24-triol monohydrate, with the empirical formula C 27 H 40 O 3 •H 2 O, a molecular weight of 430.6, and the following structural formula: Calcipotriene monohydrate is a white or off-white crystalline substance. Calcipotriene Cream contains calcipotriene monohydrate equivalent to 50 μg/g anhydrous calcipotriene in a cream base of cetearyl alcohol, ceteth-20, diazolidinyl urea, dichlorobenzyl alcohol, dibasic sodium phosphate, edetate disodium, dl-alpha tocopherol, glycerin, mineral oil, petrolatum, and water.

Structural formula for calcipotriene monohydrate

💬 Information for Patients 106 words ▾

Information for Patients Patients using Calcipotriene Cream should receive the following information and instructions: This medication is to be used only as directed by the physician. It is for external use only. Avoid contact with the face or eyes.

As with any topical medication, patients should wash their hands after application. This medication should not be used for any disorder other than that for which it was prescribed. Patients should report to their physician any signs of adverse reactions.

Patients that apply Calcipotriene Cream to exposed portions of the body should avoid excessive exposure to either natural or artificial sunlight (including tanning booths, sun lamps, etc.).

Source: FDA Structured Product Labeling, mirrored from DailyMed / openFDA. Prefer the government’s original formatting? View this label on DailyMed ↗
← 66993-0832-02 · Prasco 66993-0878-61 · Prasco →
For educational and professional reference only — not medical advice. Pricing reflects published NADAC and CMS ASP (free public data) and may differ from your acquisition cost; always verify before billing or dispensing.